Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model.
Allogeneic human mesenchymal stem cells (hMSCs) introduced intravenously can have profound anti-inflammatory activity resulting in suppression of graft vs. host disease as well as regenerative events in the case of stroke, infarct, spinal cord injury, meniscus regeneration, tendinitis, acute renal failure, and heart disease in human and animal models of these diseases. hMSCs produce bioactive factors that provide molecular cuing for: 1) immunosuppression of T cells; 2) antiscarring; 3) angiogenesis; 4) antiapoptosis; and 5) regeneration (i.e., mitotic for host-derived progenitor cells). Studies have shown that hMSCs have profound effects on the immune system and are well-tolerated and therapeutically active in immunocompetent rodent models of multiple sclerosis and stroke. Furthermore, intravenous administration of MSCs results in pulmonary localization. Asthma is a major debilitating pulmonary disease that impacts in excess of 150 million people in the world with uncontrolled asthma potentially leading to death. In addition, the socioeconomic impact of asthma-associated illnesses at the pediatric and adult level are in the millions of dollars in healthcare costs and lost days of work. hMSCs may provide a viable multiaction therapeutic for this inflammatory lung disease by secreting bioactive factors or directing cellular activity. Our studies show the effectiveness and specificity of the hMSCs on decreasing chronic airway inflammation associated with the murine ovalbumin model of asthma. In addition, the results from these studies verify the in vivo immunoeffectiveness of hMSCs in rodents and support the potential therapeutic use of hMSCs for the treatment of airway inflammation associated with chronic asthma.
Bonfield
Tracey L
TL
Dept. of Pediatrics, Case Western Reserve Univ., Cleveland, OH 44106-4948, USA. tracey.bonfield@case.edu
Koloze
Mary
M
Lennon
Donald P
DP
Zuchowski
Brandon
B
Yang
Sung Eun
SE
Caplan
Arnold I
AI
D000328:Adult; D000818:Animals; D001249:Asthma / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002648:Child; D016207:Cytokines / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007371:Interferon-gamma / Q000276:immunology; D053583:Interleukin-1beta / Q000276:immunology; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000378:metabolism; D010047:Ovalbumin / Q000494:pharmacology*; D011014:Pneumonia / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D016207:Cytokines; D053583:Interleukin-1beta; D009569:Nitric Oxide; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin
Arthritis Res Ther. 2007;9(1):301
17284303
Regen Med. 2007 Sep;2(5):817-29
17907933
J Intern Med. 2007 Nov;262(5):509-25
17949362
Circulation. 2005 Jul 12;112(2):214-23
15998673
FASEB J. 2007 Oct;21(12):3197-207
17496162
Am J Pathol. 2002 Aug;161(2):491-8
12163374
Nat Rev Drug Discov. 2004 Oct;3(10):831-44
15459674
J Immunol. 2008 Sep 15;181(6):4389-96
18768898
Cytotherapy. 2006;8(4):315-7
16923606
J Leukoc Biol. 2004 Feb;75(2):163-89
14525967
Cells Tissues Organs. 2001;169(1):12-20
11340257
Clin Diagn Lab Immunol. 2005 Jul;12(7):821-4
16002629
Cell Immunol. 2002 Oct;219(2):92-7
12576027
Regen Med. 2006 Jul;1(4):497-509
17465844
Cell Stem Cell. 2008 Sep 11;3(3):229-30
18786406
J Bone Miner Res. 1999 May;14(5):700-9
10320518
Am J Respir Crit Care Med. 1999 Dec;160(6):2040-7
10588626
Am J Respir Crit Care Med. 1995 Aug;152(2):800-3
7633745
Adv Exp Med Biol. 2006;585:49-64
17120776
Curr Opin Allergy Clin Immunol. 2005 Apr;5(2):161-6
15764907
Exp Hematol. 2000 Aug;28(8):875-84
10989188
Stem Cells. 2007 Nov;25(11):2739-49
17656645
J Pediatr. 1997 Sep;131(3):381-5
9329413
Proc Am Thorac Soc. 2008 Aug 15;5(6):711-6
18684723
Exp Hematol. 2006 Nov;34(11):1604-5
17046583
J Immunol. 2008 Jul 1;181(1):235-42
18566389
Cell Mol Biol (Noisy-le-grand). 2003 Sep;49(6):875-84
14656045
J Clin Invest. 2003 Feb;111(3):291-7
12569150
Ann Allergy Asthma Immunol. 2003 Jan;90(1 Suppl 1):1-40
12542071
Cytokine Growth Factor Rev. 2003 Dec;14(6):489-502
14563351
J Allergy Clin Immunol. 2006 Jan;117(1):111-8
16387593
BioDrugs. 2004;18(4):211-23
15244499
Connect Tissue Res. 1996;35(1-4):93-9
9084647
Lancet. 2008 May 10;371(9624):1579-86
18468541
Monaldi Arch Chest Dis. 2006 Mar;65(1):47-51
16700195
Cell Stem Cell. 2008 Sep 11;3(3):301-13
18786417
Annu Rev Immunol. 2004;22:789-815
15032597
Curr Opin Allergy Clin Immunol. 2001 Dec;1(6):555-60
11964741
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11
12815096
Int J Cardiol. 2004 Jun;95 Suppl 1:S23-5
15336840
Methods Cell Biol. 2008;86:295-309
18442653
J Neurol Sci. 2008 Nov 15;274(1-2):68-75
18789804
Exp Toxicol Pathol. 2006 Jun;57 Suppl 2:3-4
16584873
Stem Cells. 2008 Sep;26(9):2287-99
18566331
Gene Ther. 2008 Jan;15(2):109-16
17989700
Trends Mol Med. 2001 Jun;7(6):259-64
11378515
Nat Med. 1999 Mar;5(3):309-13
10086387
Curr Opin Lipidol. 2007 Dec;18(6):645-9
17993810
J Pathol. 2009 Jan;217(2):318-24
19023885
J Cell Biochem. 2006 Aug 1;98(5):1076-84
16619257